Amoxiclav quicktab dispersible tablets 1000mg (875mg+125mg) №2×5

Name:
Amoxiclav quicktab tab disp. 1000mg (875mg + 125mg) in bl in pack No. 2×5
Description:
Dispersible tablets 875mg/125mg: Yellow-brown, speckled, octagonal tablets with an aromatic odor. Main active ingredient Amoxicillin + clavulanic acid Release form Tablets Dosage Each 875 mg / 125 mg tablet contains: 875 mg of amoxicillin in the form of trihydrate and 125 mg of clavulanic acid in the form of potassium salt Pharmacological properties Amoxiclav Quiktab is a broad-spectrum antibiotic used to treat infectious diseases. It belongs to a group of beta-lactam antibiotics called penicillins. The drug is a combination of two active substances: amoxicillin and clavulanic acid. Amoxicillin kills bacteria that cause infections, while clavulanic acid protects amoxicillin from destruction. Thus, the combination of amoxicillin and clavulanic acid is active against many microorganisms that produce beta-lactamase resistant to the action of amoxicillin alone. Indications for use Amoxiclav Quiktab is indicated for the treatment of the following infections in adults and children: acute bacterial sinusitis; acute otitis media; acute bronchitis, exacerbation of chronic bronchitis; community-acquired pneumonia; cystitis; pyelonephritis; infections of the skin and soft tissues, in particular inflammation of the subcutaneous tissue, wounds from animal bites, severe tooth abscess with widespread phlegmon; infections of bones and joints, in particular osteomyelitis. Route of administration and doses Doses reflect the content of amoxicillin / clavulanic acid. When choosing a dose for the treatment of specific infections, the following factors should be considered: suspected infectious agents and their possible susceptibility to antibacterial drugs; the severity and location of the infection; age, weight of the patient and kidney function, as indicated below. The use of other dosage forms of the drug (for example, with higher doses of amoxicillin and / or with a different dose ratio of amoxicillin / clavulanic acid) is considered as necessary. If you need a higher daily dose of amoxicillin, it is recommended to choose a different dosage form of the drug in order to avoid taking excessively high daily doses of clavulanic acid. The duration of therapy is determined by the response to treatment. Some infections (such as osteomyelitis) require longer treatment. The duration of treatment should not exceed 14 days without revision (see information on long-term therapy in the Precautions section). Adults and children over 12 years of age and weighing at least 40 kg Recommended doses: standard dose (for all indications) – one 500 mg / 125 mg tablet three times a day (every 8 hours) or one 875 mg / 125 mg tablet two times a day (every 12 hours); a higher dose (in more severe cases) is one 875 mg/125 mg tablet three times a day (every 8 hours). Children under 12 years of age weighing <40 kg Recommended dosing regimen for 500 mg/125 mg dispersible tablets: 20 mg/5 mg/kg/day to 60 mg/15 mg/kg/day, in 3 divided doses. Recommended dosage regimen for 875 mg/125 mg dispersible tablets: 25 mg/3.6 mg/kg/day to 45 mg/6.4 mg/kg/day, in 2 divided doses; Possible dosing regimen 2 times a day at a dose of up to 70 mg / 10 mg / kg / day for certain infections (such as otitis media, sinusitis and infections of the lower respiratory tract). In children under 2 years of age, there is no experience of using the drug at a dosage of 500 mg / 125 mg at a dose of more than 40 mg / 10 mg / kg per day, as well as a dosage of 875 mg / 125 mg at a dose of more than 45 mg / 6.4 mg / day. kg per day. Clinical data on the use of the drug in patients younger than 2 months are not available, and therefore there are no dosage recommendations for this age group. Elderly patients Dose adjustment is not required. Patients with impaired renal function (adults and children> 40 kg) – a slight impairment of function (creatinine clearance> 30 ml / min): the dose does not change; – Moderate impairment of function (creatinine clearance 10 – 30 ml/min): one tablet 500 mg/125 mg every 12 hours, the use of tablets 875 mg/125 mg is not recommended; – severe impairment of function (creatinine clearance <10 ml / min): one tablet 500 mg / 125 mg once a day, the use of tablets 875 mg / 125 mg is not recommended; - patients on hemodialysis: one 500 mg/125 mg tablet per day, plus 500 mg/125 mg during dialysis and again at the end of dialysis (as serum concentrations of amoxicillin and clavulanic acid decrease). Patients with impaired liver function Use with caution. Monitor liver function regularly. Experience with the use of the drug in patients with hepatic insufficiency is insufficient to make specific recommendations for dosing (see "Contraindications" and "Precautions"). How to use Break the blister along the perforated line, fold back the colored triangle and pull off the cover. Do not try to squeeze the tablet out of the foil. Immediately before use, the tablet should be dissolved in water (not less than 50 ml) and the resulting mixture should be thoroughly mixed. It is not recommended to swallow the tablet whole. Take immediately before meals to minimize possible gastrointestinal side effects. Use during pregnancy and lactation If you are pregnant (or think you are pregnant) or breast-feeding, inform your doctor. necessary. Both active ingredients are excreted in breast milk (data on the effect of clavulanic acid on breastfed children are not available). Breastfed babies may develop diarrhea and fungal infections of the mucous membranes, which may require stopping breastfeeding. The possibility of sensitization should be considered. Therapy with the drug during breastfeeding is possible only after assessing the benefit-risk ratio by the attending physician. Precautions Do not take Amoxiclav Quiktab if you are allergic to penicillins, cephalosporins or other beta-lactam drugs. There have been reports of the development of serious hypersensitivity reactions, sometimes fatal, (including anaphylactoid and severe skin adverse reactions) in patients receiving penicillin therapy. They are most likely to develop in patients with hypersensitivity reactions to penicillins and a history of atopy. If an allergic reaction develops, Amoxiclav Quiktab therapy is stopped, and other suitable antibacterial drugs are taken instead. This dosage form of the drug is not suitable for use if there is a high risk that the alleged pathogens are resistant, due not to the production of beta-lactamase sensitive to clavulanic acid inhibition, but to a change in penicillin-binding proteins (including resistant S. pneumoniae). In patients with impaired renal function or receiving high-dose therapy, seizures may develop (see "Side Effects"). Taking Amoxiclav Quiktab should be avoided if infectious mononucleosis is suspected, since after the use of amoxicillin against the background of this disease, the appearance of a measles-like rash was observed. The concomitant use of allopurinol during treatment with amoxicillin potentially increases the likelihood of allergic skin reactions. Prolonged use of Amoxiclav Quiktab may lead to overgrowth of non-susceptible microorganisms. The development of generalized erythema with fever and pustules at the beginning of therapy is a potential symptom of acute generalized exanthematous pustulosis (AGEP). Such a reaction requires discontinuation of Amoxiclav Quiktab therapy and is a contraindication to the subsequent use of amoxicillin. Caution should be exercised when treating patients with hepatic impairment. Adverse events from the liver were observed mainly in men and elderly patients and are potentially associated with long-term treatment. These adverse events in very rare cases were observed in children. In all groups of patients, signs and symptoms usually occur during or shortly after treatment, but in some cases they do not appear until a few weeks after stopping therapy. They are usually reversible. Serious adverse events from the liver can develop, extremely rarely with a fatal outcome. They were almost always observed among patients with serious underlying diseases or taking concomitant drugs that can damage the liver. Cases of antibiotic-associated colitis observed during therapy with almost all antibacterial drugs, including amoxicillin, can vary in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients with diarrhea during or after completion of any course of antibiotic therapy. In the event of the development of antibiotic-associated colitis, Amoxiclav Quiktab therapy should be stopped immediately, consult a doctor and start appropriate treatment. In this situation, the use of drugs that depress peristalsis is contraindicated. During long-term therapy, periodic evaluation of the functions of various organ systems, including the kidneys, liver, and hematopoietic organs, is recommended. In rare cases, while taking the drug, prolongation of prothrombin time was noted. When taking anticoagulants at the same time, proper monitoring of coagulation parameters is mandatory. Dose adjustment of oral anticoagulants may be required to achieve the desired level of anticoagulation. In patients with renal insufficiency, dose adjustment is mandatory in accordance with the level of insufficiency (see "Doses and method of administration"). In patients with reduced diuresis, crystalluria was observed in rare cases, mainly against the background of parenteral therapy. During therapy with high doses of amoxicillin, sufficient fluid intake and diuresis control are recommended to reduce the likelihood of amoxicillin-associated crystalluria. In patients with an established urinary catheter, it is imperative to regularly monitor its patency. If it is necessary to evaluate the level of glucose in the urine during treatment with amoxicillin, enzymatic methods with glucose oxidase should be used, since non-enzymatic methods sometimes give false positive results. The presence of clavulanic acid in Amoxiclav Quiktab may cause false positive Coombs test results. There have been cases of positive results of enzyme-linked immunosorbent assay (ELISA) for Aspergillus in patients treated with the drug, in which the absence of Aspergillus infections was subsequently determined. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses have been noted in the ELISA test for Aspergillus. Positive test results in patients taking Amoxiclav Quiktab should be interpreted with caution and confirmed by other diagnostic methods. Each dispersible tablet of Amoxiclav Quiktab 500 mg/125 mg contains 6.5 mg of aspartame, each dispersible tablet of 875 mg/125 mg contains 9.5 mg of aspartame. In this regard, patients with phenylketonuria should be careful when taking this drug. Amoxiclav Quiktab also contains hydrogenated castor oil (26 mg per 500 mg/125 mg dispersible tablet and 36 mg per 875 mg/125 mg dispersible tablet), which can cause dyspepsia and diarrhea. Interactions with other drugs If you have recently taken other drugs, including over-the-counter drugs, please tell your doctor or pharmacist. In particular, you should call your doctor's attention if you are taking - oral anticoagulants (eg, acenocoumarol, warfarin), - methotrexate, - probenecid, - mycophenolate mofetil. Contraindications Hypersensitivity to the active or excipients of the drug, as well as to any penicillins. History of severe immediate hypersensitivity reactions (eg, anaphylaxis) to other beta-lactam drugs (eg, cephalosporins, carbapenems, or monobactams). History of jaundice or other liver damage associated with the use of amoxicillin / clavulanic acid. Composition Each 875 mg/125 mg tablet contains: 875 mg amoxicillin trihydrate and 125 mg clavulanic acid potassium salt. Excipients: tropical blend flavor, sweet orange flavor, aspartame, colloidal silicon dioxide, iron oxide III (yellow) E 172, talc, hydrogenated castor oil, silicified microcrystalline cellulose. Overdose If you have taken a higher dose than you should, seek medical attention immediately. Show your package of tablets to your doctor. Gastrointestinal symptoms may develop, as well as fluid and electrolyte imbalance. There have been cases of amoxicillin-associated crystalluria, sometimes leading to renal failure. Patients with impaired renal function or those receiving high dose therapy may develop convulsions. Side effects The most frequently reported adverse reactions are diarrhea, nausea and vomiting. The following categories were used to classify the incidence of adverse reactions: very common (? 1/10), frequent (from ? 1/100 to < 1/10), infrequent (from ? 1/1000 to < 1/100), rare ( from ? 1/10,000 to < 1/1,000), very rare (< 1/10,000), unknown frequency (estimation from the available data is not possible). Infectious and parasitic diseases Frequent: candidiasis of the skin and mucous membranes. Unknown frequency: overgrowth of non-susceptible organisms. Blood and lymphatic system disorders Rare: reversible leukopenia (including neutropenia), thrombocytopenia. Unknown frequency: reversible agranulocytosis, hemolytic anemia, prolongation of bleeding time and prothrombin time. Immune system disorders Unknown frequency: angioedema, anaphylaxis, serum syndrome, allergic vasculitis. Nervous system disorders Uncommon: dizziness, headache. Unknown frequency: reversible hyperactivity, convulsions, aseptic meningitis. Gastrointestinal disorders Very common: diarrhoea. Common: Nausea (often associated with high oral doses; gastrointestinal reactions can be minimized if the drug is taken at the start of a meal), vomiting. Uncommon: indigestion. Unknown frequency: antibiotic-associated colitis (including pseudomembranous colitis and hemorrhagic colitis, see Precautions section), black tongue. Liver and biliary tract disorders Uncommon: Elevated AST and/or ALT levels (moderate increases have been reported in patients treated with beta-lactam antibiotics, but the significance of these observations is unknown). Unknown frequency: hepatitis, cholestatic jaundice (these adverse events were observed against the background of the use of other penicillins and cephalosporins, see "Precautions"). Skin and subcutaneous tissue disorders Treatment should be discontinued if any allergic skin reaction develops. Uncommon: skin rash, itching, urticaria. Rare: erythema multiforme. Unknown frequency: Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Renal and urinary disorders Unknown frequency: interstitial nephritis, crystalluria. Storage conditionsKeep out of the reach of children.Keep in a place protected from moisture, in the original packaging, at a temperature not exceeding 25?C. Buy Amoxiclav quicktab dispersible tablets 1000mg (875mg+125mg) №2x5